TABLE 2.
Presentation | Liver biopsy | Cirrhosis | Fibrosis | Steatosis | Inflammatory activity |
---|---|---|---|---|---|
Diagnostic liver biopsies
| |||||
Asymptomatic, (n=14) | 5 | 2 | 3 | 4 | 5 |
Hepatic (n=13) | 6 | 4 | 6 | 5 | 5 |
Neurological (n=15) | 5 | 2 | 4 | 1 | 3 |
Hepatic and neurological (n=6) | 4 | 4 | 4 | 3 | 1 |
Total (n=48) | 20 | 12 | 17 | 13 | 14 |
Follow-up liver biopsies
| |||||
Asymptomatic, (n=14) | 4 | 1 | 4 | 3 | 1 |
Hepatic (n=13) | 4 | 3 | 4 | 1 | 3 |
Neurological (n=15) | 4 | 3 | 4 | 3 | 2 |
Hepatic and neurological (n=6) | 2 | 2 | 2 | 1 | 1 |
Total (n=48) | 14 | 9 | 14 | 8 | 7 |
Data presented as n. Results are divided into patients with diagnostic biopsies before and up to one year postdiagnosis, and those with follow-up biopsies, performed one year or greater postdiagnosis (some patients had both diagnostic and follow-up biopsies performed). Median time between diagnostic biopsies and treatment initiation, and follow-up biopsies and treatment initiation is −41 days (range −25.2 to +8.1 months) and 8.2 years (range 1.5 to 33.0 years), respectively. Due to lack of standardization in the pathology reporting, fibrosis was counted if it was documented in the report and may or may not have been graded. Similarly, cirrhosis and steatosis were counted if they were documented in the report and range from mild to severe. Inflammatory activity was counted if the report documented hepatitis or presence of inflammatory cell infiltrate